Yttrium-90 radioembolization for the treatment of unresectable hepatocellular carcinoma in patients with transjugular intrahepatic portosystemic shunts

Keyphrases

• Unresectable Hepatocellular Carcinoma 100%
• Yttrium-90 Radioembolization 100%
• Transjugular Intrahepatic Portosystemic Shunt 100%
• Liver Transplantation 60%
• Median Survival 40%
• Confidence Interval 40%
• World Health Organization 40%
• Imaging Response 40%
• European Association for the Study of the Liver 40%
• Effective Treatment 20%
• Radioembolization 20%
• Hepatocellular Carcinoma 20%
• Common Terminology Criteria for Adverse Events (CTCAE) 20%
• Days of Treatment 20%
• Safe Treatment 20%
• Encephalopathy 20%
• Yttrium-90 20%
• Abdominal Pain 20%
• National Cancer Institute Common Terminology Criteria for Adverse Events 20%
• Kaplan-Meier Method 20%
• Index Lesion 20%
• Clinical Toxicity 20%
• Bilirubin Neurotoxicity 20%
• Glass Microspheres 20%

Medicine and Dentistry

• Hepatocellular Carcinoma 100%
• Transjugular Intrahepatic Portosystemic Shunt 100%
• Radioembolization 100%
• Yttrium 90 100%
• Liver Transplantation 60%
• Bilirubin 20%
• Adverse Event 20%
• Infusion 20%
• Abdominal Pain 20%
• Malignant Neoplasm 20%
• Kaplan Meier Method 20%
• Brain Disease 20%
• Microsphere 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Liver Cell Carcinoma 100%
• Yttrium 90 100%
• Malignant Neoplasm 20%
• Adverse Event 20%
• Brain Disease 20%
• Abdominal Pain 20%
• Bilirubin 20%
• Microsphere 20%